about
The circadian clock in cancer development and therapySystems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence"Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge aheadAnalysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.Cancer heterogeneity is not compatible with one unique cancer cell metabolic mapProfiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition.Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous nicheDiscrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature.Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype.Serum lactate dehydrogenase and survival following cancer diagnosis.Low-carbohydrate, high-protein diet score and risk of incident cancer; a prospective cohort study.Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinomaPrognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma.Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo.Integrated regulation of the cellular metabolism and function of immune cells in adipose tissue.Arginine dependence of tumor cells: targeting a chink in cancer's armor.PKM2, cancer metabolism, and the road ahead.Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.Simultaneous Quantification of Serum Multi-Phospholipids as Potential Biomarkers for Differentiating Different Pathophysiological states of lung, stomach, intestine, and pancreasMeasurement of the acute metabolic response to hypoxia in rat tumours in vivo using magnetic resonance spectroscopy and hyperpolarised pyruvate.Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.ROS-independent ER stress-mediated NRF2 activation promotes warburg effect to maintain stemness-associated properties of cancer-initiating cells.A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma.Metabolomics Analyses of Cancer Cells in Controlled Microenvironments.MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts.DNMT1 mediates metabolic reprogramming induced by Epstein-Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma.The implications of signaling lipids in cancer metastasisRewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism
P2860
Q28390451-94CEA30F-6473-4AA2-AE1E-2EE86F2005ACQ28391909-478F8E9A-CC66-48D6-A98E-711928DD1BCBQ28397132-C5FAF149-62F3-4808-8FFB-C62BCE25E257Q30928926-B58576A1-4E55-4002-B86F-E16F5BBFA329Q33721222-3E9EABFE-54D8-41FA-892F-689F55A727ACQ33877459-8E373703-4CF2-4B26-ABD2-02BAE29EC471Q35288003-FCDA4C5B-E92E-43DF-A4BF-C9D0A731ACFCQ35717532-C18929A0-EC03-41D7-8204-2C36171BEC16Q36454678-E34E5ACB-D3CE-42BC-A56A-E0EB6D6313F8Q36484135-A0AE4CB8-471F-41F4-9A36-901059A67A05Q36750612-CAC90288-3DAD-43ED-A187-492A91DAD170Q36846778-99E3A008-CB3E-408F-8616-2640D4D49E2FQ37327988-95D6F60D-E9CA-4EB0-9F0E-833D628021DDQ37329542-5ECE4506-48B1-49D7-8596-C6846759ECA6Q37649672-8CB9F6BD-62AA-441D-A922-9C6BFE8042A2Q37718416-4FBA0118-5A24-45EC-A213-95523DCBCD3CQ38686210-D0F3BEF2-2A42-4A98-B179-F98E3DC7F353Q38816145-37EE4F79-B036-4C71-BEB1-7780CAED30DAQ39011310-5EE3494C-366E-4212-9BA5-2C659F63CCEBQ39029196-BF98E7D9-BBDE-4718-A143-77077B5159ADQ39378337-8814D2A1-6620-49BB-BEAA-767FD79779B9Q41440976-A6090EEE-BECB-4A9D-B281-A546C0F8FA4CQ42105142-1A37966A-36BD-4188-AB2F-E1F3FADBC1EDQ48131479-FB50A30D-D9D1-4F9E-B512-793CCA8EEF01Q50130132-631CB26D-AA0F-4603-BF7A-29FAB75EF44CQ52576032-4A208556-3A7C-4F02-B7D4-7158255B48ABQ52944102-9F50605B-7B55-4D09-83E9-CDE77A1BCA3BQ54239289-324734C8-7D68-4D2C-8574-D01BBC499F19Q55281574-21E48836-A2E6-40C0-8B57-A9F81AF53922Q58705856-9A476218-5463-4605-8FAA-14460BA67FFEQ58788944-8FFDD632-5DAA-4B4B-9C9A-E63DF11B648D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Metabolic reprogramming of the tumor.
@en
Metabolic reprogramming of the tumor.
@nl
type
label
Metabolic reprogramming of the tumor.
@en
Metabolic reprogramming of the tumor.
@nl
prefLabel
Metabolic reprogramming of the tumor.
@en
Metabolic reprogramming of the tumor.
@nl
P2860
P356
P1433
P1476
Metabolic reprogramming of the tumor
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2011.576
P407
P577
2012-01-09T00:00:00Z